E-mail

E-mail a Wiley Online Library Link

Susan Urba, Carla M. L. van Herpen, Tarini Prasad Sahoo, Dong M. Shin, Lisa Licitra, Klara Mezei, Christoph Reuter, Ricardo Hitt, Francesca Russo, Shao-Chun Chang, Anwar M. Hossain, Bente Frimodt-Moller, Andrew Koustenis and Ruey-Long Hong Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer Cancer 118

Version of Record online: 20 MAR 2012 | DOI: 10.1002/cncr.27449

In a double-blind, placebo-controlled, phase 3 trial, patients with recurrent or metastatic squamous cell carcinoma of the head and neck are randomized to pemetrexed plus cisplatin or placebo plus cisplatin to assess overall survival and secondary endpoints. Pemetrexed-cisplatin does not significantly improve survival for the intention-to-treat population. However, in a preplanned subgroup analysis, pemetrexed-cisplatin leads to longer overall survival and progression-free survival for patients with performance status 0 or 1 and patients with oropharyngeal cancers.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH